Accession Number : ADA585851


Title :   Regulation and Function of TIFAB in Myelodysplastic Syndrome


Descriptive Note : Annual rept. 1 Jun 2012-30 May 2013


Corporate Author : CHILDREN'S HOSPITAL MEDICAL CENTER CINCINNATI OH


Personal Author(s) : Starczynowski, Daniel


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA585851


Report Date : Jun 2013


Pagination or Media Count : 27


Abstract : Myelodysplastic syndromes (MDS) are clonal bone marrow failure (BMF) disorders defined by blood cytopenias due to ineffective hematopoiesis, genomic instability, and a predisposition to acute myeloid leukemia (AML). The most commonly recurring genomic alteration in MDS is deletion of chromosome 5q (del(5q)). MDS patients with an isolated del(5q) presenting with anemia, neutropenia, and elevated platelets associated with dysplastic megakaryocytes are considered to have 5q- syndrome. The majority of MDS patients with del(5q) do not exhibit these particular symptoms and, instead, are referred to as del(5q) MDS . We have recently identified miR- 146a, which target the TRAF6 arm of the innate immune pathway, a gene within the deleted region in del(5q) MDS. We posit that multiple genes on chr 5q coordinate TRAF6 activation in del(5q) MDS. A search of annotated genes within or near the CDRs revealed a known inhibitor of TRAF6, TIFAB, on band q31.1. We hypothesize that deletion of TIFAB promotes activation of the TRAF6 complex in human CD34+ cells resulting in hematopoietic defects resembling MDS with del(5q). The overall objectives of this proposal are to (1) determine whether loss of TIFAB in human CD34+ cells contributes to MDS in mice; (2) to investigate whether deletions of TIFAB activate TRAF6 in MDS; and (3) to determine the consequences of TIFAB deletion on signal transduction in human CD34+ cells, and whether these could explain features of MDS. In preliminary data from the first 2 year of the proposal, we have evidence that TIFAB is a regulator of human hematopoietic cells. Our key observations show that knockdown of TIFAB in human CD34+ hematopoietic stem/progenitor cells results in increased survival and proliferation, TIFAB inhibits TRAF6 protein expression and activation, resulting in lower NF-kB activation, and TIFAB expression impacts leukemic cell survival, growth and progenitor function. Given that TIFAB is deleted in many MDS patients, these findings cou


Descriptors :   *BONE MARROW , BLOOD PLATELETS , CHROMOSOMES , FAILURE , GENOME , HEMATOPOIETIC SYSTEM , SIGNS AND SYMPTOMS , SURVIVABILITY


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE